StockData
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. (VVOS) stock

VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 3/30
$0.10+0.00 (+2.40%)

Close on Nov 13, 2026Market cap $1.97MP/E –Yield –

Vivos Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Vivos Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 61.9%. For fiscal 2025 it was 60.4%, against 60.0% the year before. The highest annual figure on record is 79.7% in fiscal 2020.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202560.4%+0.4
FY2024Dec 31, 202460.0%+0.1
FY2023Dec 31, 202359.9%−2.6
FY2022Dec 31, 202262.5%−12.1
FY2021Dec 31, 202174.6%−5.0
FY2020Dec 31, 202079.7%+3.7
FY2019Dec 31, 201976.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202657.3%+2.1
Q1 FY2026Mar 31, 202659.5%+9.5
Q4 FY2025Dec 31, 202578.1%+21.4
Q3 FY2025Sep 30, 202558.0%−2.4
Q2 FY2025Jun 30, 202555.2%−10.2
Q1 FY2025Mar 31, 202550.0%−6.6
Q4 FY2024Dec 31, 202456.7%−7.6
Q3 FY2024Sep 30, 202460.5%+7.5
Q2 FY2024Jun 30, 202465.4%+3.6
Q1 FY2024Mar 31, 202456.7%−3.9
Q4 FY2023Dec 31, 202364.3%+4.0
Q3 FY2023Sep 30, 202352.9%−5.9
Q2 FY2023Jun 30, 202361.8%−0.1
Q1 FY2023Mar 31, 202360.6%−9.4
Q4 FY2022Dec 31, 202260.4%−10.4
Q3 FY2022Sep 30, 202258.8%−11.2
Q2 FY2022Jun 30, 202261.9%−18.7
Q1 FY2022Mar 31, 202270.0%−8.0
Q4 FY2021Dec 31, 202170.7%−10.6
Q3 FY2021Sep 30, 202170.0%−8.4
Q2 FY2021Jun 30, 202180.6%−2.8
Q1 FY2021Mar 31, 202178.0%+2.4
Q4 FY2020Dec 31, 202081.3%–
Q3 FY2020Sep 30, 202078.5%–
Q2 FY2020Jun 30, 202083.3%–
Q1 FY2020Mar 31, 202075.6%–

More Vivos Therapeutics figures

See a number that looks wrong?